Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The abstract for the RELEVANCE/LY.16 study was presented at ASCO on June 3rd, 2018. This study compared the effects of lenalidomide plus rituximab (R2) to chemotherapy plus rituximab (R-chemo) followed by rituximab maintenance in patients with previously untreated follicular lymphoma.
The CCTG TRIALBLAZERS have been training hard for this year’s Kingston Relay for Life, June 22, 2018 - 6:00 pm - 12:00 am.
The PRODIGE 24/CCTG PA.6 trial results suggest that this pancreatic cancer treatment regimen should become standard practice world-wide. Patients who receive this treatment after surgery are almost twice as likely to survive.
New results from the groundbreaking “Trial Assigning Individualized Options for Treatment Rx” (TAILORx) breast cancer trial (CCTG MAC.12 in Canada), show no benefit from chemotherapy for 70% of women with the most common form of breast cancer. The study found that for a group of women with hormone receptor (HR)-positive, HER2 negative, axillary lymph node-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more beneficial than with hormone therapy alone.
The Canadian Cancer Trials Group's (CCTG) Supportive Care (former Symptom Control) Committee (SCC) is currently seeking individuals with interest and experience in supportive care trials to join the SCC Executive. In broad terms (adapted from the CCTG's Terms of Reference) the roles of the Disease Site Committee (DSC) Executive members are to:
A great opportunity to join our team: The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a Monitor/Auditor. Position Title: Monitor/Auditor Competition Number: J0518-0333
Bladder cancer hit the world stage with an oral presentation at ASCO this past weekend. The presentation of the results of the study was given by Dr. Srikala Sridhar, BL12 Study Chair, at the general meeting in Chicago. Bladder cancer is the 5th most common cancer in Canada with 9000 new cases annually. For patients with advanced disease who progress on first line chemotherapy, options include immunotherapy or taxane-based chemotherapy.
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery. The randomized phase III clinical trial was sponsored by the academic cancer research groups of UNICANCER, in Paris, France and the Canadian Cancer Trials Group (CCTG).
